Axxent MPX Controller Specifications		Part Number
Axxent MPX Controller High Voltage Output Beam Current	50 kV (selectable) 300 μA	XP1100
Dimensions		
Height Width Depth Weight Maximum Inclination	52 in (133 cm) 21 in (53 cm) 31 in (79 cm) 202 lb (92 kg) 10 degrees	
Power Specifications		
Line Power Ion Cailibration Chamber Manufacturer/Model Electrometer Manufacturer/Model	100-120 V~, 220-240 V~, 150 VA Standard Imaging/HDR 1000 Plus Standard Imaging/Max 4000	

Axxent HDR X-ray Source 2.2 S	Specifications	Part Number
Axxent HDR X-ray Source X-ray Tube Diameter Assembly Length Assembly Diameter X-ray Source Power	2.25 mm 250 mm 5.4 mm 15 Watts	\$7500
Source Includes		
Nominal Dose Rate	0.6 Gy/min @ 3	cm in water

Axxent Balloon Applicator – Specifications	IORT Part Number	APBI Part Number		
Available Diameter/Volume				
3-4 cm Spherical Balloon Applicator/30-45 cc	AT2034	AB2034		
4-5 cm Spherical Balloon Applicator/45-75 cc	AT2045	AB2045		
5-6 cm Spherical Balloon Applicator/65-130 cc	AT2056	AB2056		
5x7 cm Ellipsoidal Balloon Applicator/90-125 cc	AT2057E (special order only)	AB2057E (special order only)		
Multiple Lumens				
Seroma Drainage Lumens				
Balloon Inflation Lumen				
50 kV X-ray Source Insertion				
Markings				
1 cm intervals along shaft				

Axxent Surface Applicator Sets – Specifications	Part Number
Surface Applicator Set (includes 4 applicators, 10 each size end caps, 2 source channels, 10 silicone gaskets, Exradin A20 Ion Chamber, applicator calibration fixtures)	SK1000
Surface Applicator Set with Elmed Clamp	SK1001
Accessories – Specifications	Part Number
Surface Applicator – diameter 10 mm	SK1010
Surface Applicator – diameter 20 mm	SK1020
Surface Applicator – diameter 35 mm	SK1035
Surface Applicator – diameter 50 mm	SK1050
Integral Tuohy-Borst Source Channel – length 190 mm	SK2050
Tuohy Borst Adaptor	SK3010
End Cap – diameter 10 mm	SK3510
End Cap – diameter 20 mm	SK3520
End Cap – diameter 35 mm	SK3535
End Cap – diameter 50 mm	SK3550

Axxent Va	ginal Applicator Set – Specification	ons Part Number
Vaginal Applicator Set (includes 4 applicators, source channels and carrying case)		AG3000
Vaginal App	olicator Set with Clamp & Base Plate	AG3005
Accessori	es – Specifications	Part Number
Vaginal App	olicator – diameter 20 mm, length 102 mm	AG3020
Vaginal Applicator – diameter 25 mm, length 103 mm		AG3025
Vaginal Applicator – diameter 30 mm, length 106 mm		AG3030
Vaginal Applicator – diameter 35 mm, length 107 mm		AG3035
Source Channel – length 15.9 cm		E1000
Applicator Clamp & Base Plate E2000 (includes adjustable clamp and 40cm x 50 cm base plate)		E2000
Personnel Protective Shield		
Small	32" x 16"	E3000
Medium	40" x 20"	E3100
Large	47" x 20"	E3200

For more information, visit www.xoftinc.com











Innovative Electronic Brachytherapy Platform

Axxent MPX





Xoft Axxent Electronic Brachytherapy System

Advanced Technology

The Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is an innovative platform technology offering significant patient, mobility and economic advantages. The Xoft System utilizes a proprietary miniaturized x-ray source to deliver radiation directly to the tumor site in or on the body. This technology targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked in the EU for use anywhere in the body, including treatment of early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers.

Xoft's unique 50kV stepping source combines high dose rate with low energy radiation, enabling the procedure to be completed under the supervision of a radiation oncologist in a minimally shielded setting. The mobility of the Xoft System coupled with its ability to treat multiple indications, gives clinicians and patients greater access to electronic brachytherapy as a treatment option.

One System. Multiple Solutions.

Breast eBx

An estimated 295,140 new cases of breast cancer will be diagnosed in the United States in 2014. Women whose breast cancer is detected at an early, localized stage may be eligible for breast conserving surgery over mastectomy. The Xoft System provides clinicians and patients innovative, early-stage breast cancer treatment modalities including intraoperative radiation therapy (IORT) and accelerated partial breast irradiation (APBI).

Peer reviewed studies have shown a single-fraction radiation treatment delivered at the time of breast conserving surgery results in similar recurrence rates when compared to external beam radiation therapy (EBRT).² Six weeks of daily EBRT treatments post-lumpectomy present logistical challenges for many patients. This may result in patients omitting follow up radiation therapy or electing mastectomy. Xoft's IORT

procedure may optimize patient compliance, as it has been shown to effectively provide the complete prescribed course of local treatment at the time of surgery.

IORT

- » Radiation therapy delivered as a single-fraction or boost treatment
- » Treatment times as little as 8 minutes
- » Increases target accuracy with lower dose to surrounding healthy tissue (e.g. heart, lung, rib)
- » Multiple sizes of flexible balloon applicators to ensure precise fit

apbi

- » Low recurrence rates and favorable cosmesis
- » Shortens course of radiation therapy from 6 weeks to 4-5 days
- » By limiting the volume of targeted breast tissue radiation dose can be increased and safely accelerated
- » Decreases breathing motion uncertainties

Skin eBx

More than 3.5 million cases of non-melanoma skin cancer (NMSC) in the form of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are diagnosed in the United States each year¹. The majority of BCC and SCC lesions are located on sun-exposed areas like the face, head, neck, and extremities, which may present challenges with cosmetic outcomes or wound healing. Xoft eBx offers these patients a painless, non-invasive alternate to surgical excision and other treatment modalities. Xoft eBx is also an ideal non-surgical option for candidates with co-morbidities or those who may be on anticoagulants.

- » Painless, non-invasive option for select patients
- » Clinically-proven safe and effective; provides a viable alternative to surgical excision of NMSC

- » Ideal for challenging anatomic locations
- » Over 6,000 NMSC patients treated
- » Supported by positive clinical data

For practices that wish to implement skin electronic brachytherapy, Xoft offers a scalable and modular program that brings together all the components necessary to perform skin eBx treatments in one comprehensive program. Comprised of hardware, software, management services and support, Xoft Skin eBx provides clinical practices with state-of-the-art technology, expert clinical guidance, and unparalleled customer support.

GYN eBx

Cervical

More than 530,000 new cases of cervical cancer are diagnosed each year worldwide. 5 Xoft's cervical applicator provides low energy, isotope-free HDR brachytherapy for intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina in a minimally shielded setting.

- y 4 tandem curvatures (straight, 15°, 30°, 45° and three ovoid sizes (2.0 cm, 2.5 cm, 3.0 cm) accommodate anatomical variations
- » Applicator design and materials reduce surface dose while providing calculated target dose to the prescription point

Endometrial

In the United States an estimated 52,630 new cases of uterine cancer will be diagnosed in 2014. A range of Xoft applicator sizes is available for the treatment of endometrial cancer. The targeted treatment follows standard HDR prescription protocol and reduces dose to the bladder and rectum in a minimally shielded setting.

- » Improved dosimetry
- » Rapid dose fall-off spares dose to surrounding healthy tissue



Product Overview



Axxent X-ray Source



Axxent Balloon Applicators



Axxent Surface Applicators



Axxent Vaginal Applicator Kit



Axxent Cervical Applicator

References

- 1. http://www.cancer.org/cancer/breastcancer/overviewquide/breast-cancer-overview-key-statistics
- Vaidya JS., et al "Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A Trial): an international, prospective, randomized, non-inferiority phase 3 trial." Lancet 2010 Jul10;376(9735):91-102. TARGIT-A Trial performed with Carl Zeiss Meditec AG Intrabeam System.
- $3. \ \ Rogers, HW, Weinstock, MA, Harris, AR, et al.\ Incidence\ estimate\ of\ nonmelanoma\ skin\ cancer\ in\ the\ United\ States, 2006.\ Arch\ Dermatol\ 2010;\ 146(3):283-287.$
- $4. \ \ http://www.cancer.org/cancer/cervicalcancer/detailed guide/cervical-cancer-key-statistics$
- www.who.int
- 6. http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-key-statistics